Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
BOTHELL, Wash., March 28, 2017 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 16th Annual Needham Healthcare Conference at 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, April 4, 2017 in New York, NY. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
A live audio webcast can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for 30 days after the live event concludes.
Link: http://wsw.com/webcast/needham80/aldr
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts: David Schull or Victoria Meissner Russo Partners, LLC (212) 845-4271 (646) 942-5627 [email protected] [email protected] Investor Relations Contact: David Walsey Alder Biopharmaceuticals (425) 408-8032 [email protected]
